Health and Fitness Health and Fitness
Fri, August 6, 2010
Thu, August 5, 2010
Wed, August 4, 2010
Tue, August 3, 2010
Mon, August 2, 2010
Fri, July 30, 2010
Thu, July 29, 2010
Wed, July 28, 2010
Tue, July 27, 2010
Mon, July 26, 2010
Fri, July 23, 2010
Thu, July 22, 2010
Wed, July 21, 2010
Tue, July 20, 2010
[ Tue, Jul 20th 2010 ] - Market Wire
00 AM EDT
Mon, July 19, 2010
Sun, July 18, 2010
Sat, July 17, 2010
Fri, July 16, 2010

ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2010 Financial Results


//health-fitness.news-articles.net/content/2010/ .. rter-and-fiscal-year-2010-financial-results.html
Published in Health and Fitness on Wednesday, July 28th 2010 at 3:41 GMT by Market Wire   Print publication without navigation


WALTHAM, Mass.--([ BUSINESS WIRE ])--[ ImmunoGen, Inc ]. (NASDAQ:IMGN), a biotechnology company that develops targeted anticancer products, today announced that the Company will host a conference call at 4:30p.m. ET on Wednesday, August 4, 2010, to discuss ImmunoGena™s financial results for the three-month period and fiscal year ended June 30, 2010. Management also will provide an update on the Company.

To access the live call by phone, dial 913-312-0379. Passcode 4241333. The call also may be accessed through the Investor Information section of the Companya™s website, [ www.immunogen.com ]. Following the live webcast, a replay of the call will be available at the same location through August 11, 2010.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cancer-cell killing agents. The Companya™s Targeted Antibody Payload (TAP) technology uses engineered antibodies to deliver one of ImmunoGena™s proprietary cancer-cell killing agents specifically to tumor targets. In addition to the Companya™s product pipeline, compounds are in clinical testing through ImmunoGena™s collaborations with Genentech (a member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. A marketing application for the most advanced compound using ImmunoGena™s TAP technology, T-DM1, was submitted to the US FDA by Genentech in July 2010. Other ImmunoGen collaborative partners include Bayer Schering Pharma AG and Amgen. More information about ImmunoGen can be found at [ www.immunogen.com ].


Publication Contributing Sources